Skip to main content
SpringerLink
Log in

Pharmakologie der Neuroleptika und relevante Mechanismen zur Behandlung von Minussymptomatik

  • Chapter
Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik

Zusammenfassung

Neuroleptika sind zu Standardarzneimitteln in der Behandlung der Schizophrenie geworden. Als pharmakologische Klasse weisen alle bekannten Neuroleptika eine gemeinsame Eigenschaft auf: den zentralen Dopaminantagonismus. Die beobachteten klinischen Unterschiede zwischen den einzelnen Neuroleptika wurden zeitweise spezifischen Wechselwirkungen mit Dopamin-rezeptorsubtypen oder mit Dopaminrezeptoren in besonderen Hirnarealen zugeschrieben. Wechselwirkungen mit anderen Neurotransmittern als Dopamin könnten ebenfalls eine Ursache der signifikanten klinischen Unterschiede sein. Neuere Untersuchungen haben bewiesen, daß der Serotoninantagonismus die antipsychotische Wirkung der Dopaminantagonisten unterstützt. Die experimentellen und klinischen Grundlagen der Dopamin- und der Serotoninhypothese werden im weiteren besprochen.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 44.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 59.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Ansoms C, De Backer-Dierick C, Vereecken JLTM (1977) Sleep disorders in patients with severe mental depression. Double-blind placebo controlled evaluation of the value of pipamperone (Dipiperon). Acta Psychiatr Scand 55: 116–122.

    Article  PubMed  CAS  Google Scholar 

  • Awouters F, Niemegeers CJE, Megens AAHP, Meert TF, Janssen PAJ (1988) The pharmacological profile of ritanserin, a very specific central serotonin S2 antagonist. Drug Dev Res 15: 61–73.

    Article  CAS  Google Scholar 

  • Balsara JJ, Jadhav JH, Chandorkar AG (1979) Effects of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology 62: 67–69.

    Article  PubMed  CAS  Google Scholar 

  • Bersani G, Bressa GM, Meco G, Marini S, Pozzi F (1990) Combined serotonin 5HT2 and dopamine D2 antagonism in schizophrenia: clinical, extrapyramidal and neuroendocrine response in a preliminary study with risperidone (R 64766). Human Psychopharmacology 5: 225–231.

    Article  Google Scholar 

  • Bersani G, Grispini A, Marini S, Pasini A, Valducci M, Ciani N (1986) Neuroleptic-induced extrapyramidal side effects: clinical perspectives with ritanserin (R 55667), a new selective 5-HT2 receptor blocking agent. Curr Ther Res 40: 492–499.

    Google Scholar 

  • Carlsson A (1975) Dopaminergic autoreceptors. In: Almgren O, Carlsson A, Engel J (eds) Chemical tools in catecholamine research, Vol II. North Holland, Amsterdam, pp 219–224.

    Google Scholar 

  • Carter CJ, Pycock CJ (1977) Possible importance of 5-hydroxytryptamine in neuroleptic-induced catalepsy in rats. Br J Pharmacol 60: 267–268.

    Google Scholar 

  • Castelao JF, Ferreira L, Gelders YG, Heylen SLE (1989) The efficacy of the D2 and 5HT2 antagonist risperidone (R 55667) in the treatment of chronic psychosis. An open dosefinding study. Schizophr Res 2: 411–415.

    Article  PubMed  CAS  Google Scholar 

  • Cerletti A, Doepfner W (1958) Spezifische Steigerung der serotoninantagonistischen Wirkung von Lysergsäurederivaten durch Methylierung des Indolstickstoffes der Lysergsäure. Helv Physiol Pharmacol Acta 16: C55–C57.

    Google Scholar 

  • Ceulemans DLS, Hoppenbrouwers M-LJA, Gelders YG, Reyntjens AJM (1985) The influence of ritanserin, a serotonin antagonist, in anxiety disorders; a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry 18: 303–305.

    Article  PubMed  CAS  Google Scholar 

  • Chang WH, Chen TY, Wu HS, Hu WH, Yeh EK (1988) Dose response curves of homovanillic acid in pre-frontal cortex and caudate following antipsychotic drugs: relation to clinical potencies. Psychopharmacology 95: 459–462.

    Article  PubMed  CAS  Google Scholar 

  • Christensen AV, Arnt J, Hyttel J, Larsen JJ, Svendsen O (1984) Pharmacological effects of a specific dopamine D1 antagonist SCH 23390 in comparison with neuroleptics. Life Sci 39: 1529–1540.

    Article  Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985a) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence. J Neural Transm 62: 1–52.

    Article  PubMed  CAS  Google Scholar 

  • Clark D, Hjorth S, Carlsson A (1985b) Dopamine receptor agonists: mechanisms underlying autoreceptor selectivity. II. Theoretical considerations. J NeuralTransm 62: 171–207.

    Article  CAS  Google Scholar 

  • Colpaert FC, Niemegeers CJE, Janssen PAJ (1982) A drug discrimination analysis of lysergic acid diethylamide (LSD): in vivo agonist and antagonist effects of purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD antagonist. J Pharmacol Exp Ther 221: 206–214.

    PubMed  CAS  Google Scholar 

  • Colpaert FC, Meert TF, Niemegeers CJE, Janssen PAJ (1985) Behavioral and 5-HT antagonist effects of ritanserin: a pure and selective antagonist of LSD discrimination in rats. Psychopharmacology 86: 45–54.

    Article  PubMed  CAS  Google Scholar 

  • Coppen A, Prange AJ, Whybrow PC, Noguera R, Paez JM (1969) Methysergide in mania. A controlled trial. Lancet II: 338–340.

    Article  Google Scholar 

  • Costall B, Fortune DH, Naylor RJ, Marsden CD, Pycock C (1975) Serotonergic involvement with neuroleptic catalepsy. Neuropharmacology 14: 859–868.

    Article  PubMed  CAS  Google Scholar 

  • Critchley MAE, Handley SE (1987) Effects in the X-maze anxiety model of agents acting at 5-HT1, and 5-HT2 receptors. Psychopharmacology 93: 502–506.

    Article  PubMed  CAS  Google Scholar 

  • Deberdt R (1976) Pipamperone (Dipiperon) in the treatment of behaviour disorders. A large-scale multicentre evaluation. Acta Psychiat Belg 76: 157–166.

    CAS  Google Scholar 

  • Declerck AC, Wauquier A, Van der Haes-Veltman PHM, Gelders Y (1987) Increase in slow-wave sleep in humans with the serotonin S2 antagonist ritanserin. Curr Ther Res 41: 427–432.

    Google Scholar 

  • De Cuyper HJA (1989) Risperidone in the treatment of chronic psychotic patients: an overview of the double-blind comparative studies. In: Ayd FJ (ed) 30 years Janssen Research in Psychiatry. Ayd Medical Communications, Baltimore, pp 115–122.

    Google Scholar 

  • Dewhurst WG (1968) Methysergide in mania. Nature 219: 506–507.

    Article  PubMed  CAS  Google Scholar 

  • Dugovic C, Wauquier A (1987) 5-HT2 receptors could be primarily involved in the regulation of slow wave sleep in the rat. Eur J Pharmacol 137: 145–146.

    Article  PubMed  CAS  Google Scholar 

  • Ehringer RH, Hornykiewicz O (1960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wochenschr 15: 1236–1239.

    Article  Google Scholar 

  • Farde L, Wiesel FA, Halldin C, Sedvall G (1988) Central D2 dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 45: 71–76.

    Article  PubMed  CAS  Google Scholar 

  • Farde L, Wiesel FA, Nordström AL, Sedvall G (1989) D1- and D2-dopamine receptor occupancy during treatment with conventional and atypical neuroleptics. Psychopharmacology 99: S28–S31.

    Article  PubMed  Google Scholar 

  • Fischer-Cornelssen KA, Ferner U (1976) An example of European multicenter trials (multi-spectral analysis of clozapine). Psychopharmacol Bull 12: 34–39.

    PubMed  CAS  Google Scholar 

  • Fish B, Campbell M, Shapiro T, Floyd A (1969) Schizophrenic children treated with methysergide (Sansert). Dis Nerv Syst 30: 534–540.

    PubMed  CAS  Google Scholar 

  • Gallant DM, Bishop MP (1968) Cinanserin (Sch 10.643): a preliminary evaluation in chronic schizophrenic patients. Curr Ther Res 10: 461–463.

    PubMed  CAS  Google Scholar 

  • Gallant DM, Bishop MP, Steele CA, Noblin CD (1963) The relationship between serotonin antagonism and tranquillizing activity. Am J Psychiatry 119: 882.

    PubMed  CAS  Google Scholar 

  • Gelders YE, Heylen SLE, Van den Bussche G, Reyntjens AJM, Janssen PAJ (1989) Risperidone, a breakthrough in antipsychotic therapy. In: Ayd FJ (ed) 30 years Janssen Research in Psychiatry. Ayd Medical Communications, Baltimore, pp 123–128.

    Google Scholar 

  • Gelders Y, Van den Bussche G, Reyntjens A, Janssen P (1986) Serotonin-S2 receptor blokkers in the treatment of chronic schizophrenia. Clin Neuropharmacol 9 (Suppl 4): 325–327.

    Google Scholar 

  • Haskovec L, Soucek K (1968) Trial of methysergide in mania. Nature 219: 507–508.

    Article  PubMed  CAS  Google Scholar 

  • Hjorth SA, Carlsson A, Clark D et al. (1983) Central dopamine receptor agonist and antagonist action of the enantiomers of 3PPP. Psychopharmacology 81: 89–99.

    Article  PubMed  CAS  Google Scholar 

  • Hjorth SA, Carlsson A, Wikström H et al. (1981) 3PPP, a new centrally acting DA-receptor agonist with selectivity for autoreceptors. Life Sci 28: 1225–1238.

    Article  PubMed  CAS  Google Scholar 

  • Holden JMC, Itil T, Keskiner A, Gannon P (1971) A critical trial of an antiserotonin compound, cinanserin, in chronic schizophrenia. J Clin Pharmacol 11: 220–226.

    CAS  Google Scholar 

  • Hyttel J (1983) SCH 23390, the first selective dopamine D1 antagonist. Eur J Pharmacol 91: 153–154.

    Article  PubMed  CAS  Google Scholar 

  • Idzikowski C, Cowen PJ, Nutt D, Mills FJ (1987) The effect of chronic ritanserin treatment on sleep and the neuroendocrine response to L-tryptophan. Psychopharmacology 93: 416–420.

    Article  PubMed  CAS  Google Scholar 

  • Idzikowski C, Mills FJ, Glennard R (1986) 5-Hydroxytryptamine-2-antagonist increases human slow wave sleep. Brain Res 378: 164–168.

    Article  PubMed  CAS  Google Scholar 

  • Iorio LC, Barnett A, Leitz FH, Houser VT, Korduba CA (1983) SCH 23390, a potential benzazepine antipsychotic with unique interaction on dopaminergic systems. J Pharmacol Exp Ther 226: 462–468.

    PubMed  CAS  Google Scholar 

  • Iversen LL (1975) Dopamine receptors in the brain. A dopamine-sensitive adenylate cyclase models synaptic receptors, illuminating antipsychotic drug action. Science 188: 1084–1089.

    Article  PubMed  CAS  Google Scholar 

  • Janssen PAJ (1987a) Does ritanserin, a potent serotonin S2 antagonist, restore energetic functions during the night. JR Soc Med 80: 409–413.

    CAS  Google Scholar 

  • Janssen PAJ (1987b) The development of new antipsychotic drugs: towards a new strategy in the management of chronic psychoses. J Drug Ther Res 12: 324–328.

    Google Scholar 

  • Janssen PAJ (1988) Die Entwicklung neuartiger Antipsychotika — ein Schritt vorwärts in der Behandlung chronischer Psychosen. In: Bergener M (ed) Fortschritt in der Behandlung chronischer Psychosen. Perimed, Erlangen, S 34–42.

    Google Scholar 

  • Janssen PAJ, Niemegeers CJE, Awouters F, Schellekens KHL, Megens AAHP, Meert TF (1988) Pharmacology of risperidone (R 64766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244: 685–693.

    PubMed  CAS  Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer H, The Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch GenPsychiatry 45: 789–796.

    Article  CAS  Google Scholar 

  • Kebabian JW, Calne DB (1979) Multiple receptors for dopamine. Nature 277: 93–96.

    Article  PubMed  CAS  Google Scholar 

  • Köhler C, Haglund L, Ögren SDO, Ängeby T (1981) Regional blockade by neuroleptic drugs of “in vivo” 3H-spiperone binding in the rat brain. Relation to blockade of apomorphine induced hyperactivity. J Neural Transm 52: 163–173.

    Article  PubMed  Google Scholar 

  • Le Fur G, Guilloux F, Uzan A (1980) In vivo blockade of dopaminergic receptors from different rat brain regions by classical and atypical neuroleptics. Biochem Pharmacol 29: 267–270.

    Article  PubMed  Google Scholar 

  • Leysen JE, Laduron PM (1977) A serotonergic component of neuroleptic receptors. Arch Int Pharmacol Ther 230: 337–339.

    CAS  Google Scholar 

  • Leysen JE, Niemegeers CJE (1985) Neuroleptics. In: Lajtha A (ed) Handbook of neurochemistry, vol 9, chapt 13. Plenum, New York, pp 331–361.

    Google Scholar 

  • Leysen JE, Gommeren W, Van Gompel P, Wynants J, Janssen PFM, Laduron PM (1985) Receptor binding properties in vitro and in vivo of ritanserin. A very potent and long acting serotonin-S2 antagonist. Mol Pharmacol 27: 600–611.

    PubMed  CAS  Google Scholar 

  • Leysen JE, Gommeren W, Eens A, de Chaffoy de Courcelles D, Stoof JC, Janssen PAJ (1988) Biochemical profile of risperidone, a new antipsychotic. J Pharmacol Exp Ther 247: 661–670.

    PubMed  CAS  Google Scholar 

  • Leysen JE, Niemegeers CJE, Tollenaere JP, Laduron PM (1978) Serotonergic component of neuroleptic receptors. Nature 272: 168–171.

    Article  PubMed  CAS  Google Scholar 

  • Maire FW, Collins LG, Marks JB (1967) Evaluation of the drug 1-methyl-d-lysergic acid butanolamide or methysergide maleate in the treatment of chronic schizophrenia. Int J Neurophysiol 3: 397–399.

    CAS  Google Scholar 

  • Maj J, Mogilnicka E, Przewlocka B (1975) Antagonistic effect of cyproheptadine in neuroleptic induced catalepsy. Pharmacol Biochem Behav 3: 25–37.

    Article  PubMed  CAS  Google Scholar 

  • Meco G, Bedini L, Bonifati V, Sonsini U (1989) Risperidone in the treatment of chronic schizophrenia with tardive dyskinesia. Curr Ther Res 46: 876–883.

    Google Scholar 

  • Meert TF (1986) A comparative study of the effects of ritanserin (R 55667) and chlordiazepoxide on rat open field behavior. Drug Dev Res 8: 197–204.

    Article  CAS  Google Scholar 

  • Meert TF, Colpaert FC (1986) The shock probe conflict procedure. A new assay responsive to benzodiazepines, barbiturates and related compounds. Psychopharmacology 88: 445–450.

    Article  PubMed  CAS  Google Scholar 

  • Mendels J (1967) The effect of methysergide (an antiserotonin agent) on schizophrenia: a preliminary report. Am J Psychiatry 124: 849–852.

    PubMed  CAS  Google Scholar 

  • Mesotten F, Suy E, Pietquin M, Burton P, Heylen S, Gelders Y (1989) Therapeutic effect and safety of increasing doses of risperidone (R 64766) in psychiatric patients. Psychopharmacology 99: 445–449.

    Article  PubMed  CAS  Google Scholar 

  • Niemegeers CJE, Janssen PAJ (1979) A systematic study of the pharmacological activities of dopamine antagonists. Life Sci 24: 2201–2216.

    Article  PubMed  CAS  Google Scholar 

  • Pangalila-Ratu Langi EA, Jansen AAI (1988) Ritanserin in the treatment of generalized anxiety disorders: a placebo-controlled trial. Hum Psychopharmacol 3: 207–212.

    Article  Google Scholar 

  • Peroutka SJ, Snyder SH (1979) Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol 16: 687–699.

    PubMed  CAS  Google Scholar 

  • Persyko I (1972) Psychiatric adverse reaction to methysergide. J Nerv Ment Dis 154: 299–301.

    Article  PubMed  CAS  Google Scholar 

  • Rapport MM (1949) Serum vasoconstrictor (serotonin) V. The presence of creatinine in the complex. A proposed structure of the vasoconstriction principle. J Biol Chem 180: 961–969.

    CAS  Google Scholar 

  • Reyntjens A, Gelders YG, Hoppenbrouwers M-LJA, Van den Bussche G (1986) Thymosthenic effects of ritanserin (R 55667), a centrally acting serotonin S2 receptor blocker. Drug Dev Res 8: 205–211.

    Article  CAS  Google Scholar 

  • Roose K, Gelders Y, Heylen S (1988) Risperidone (R 64766) in psychotic patients: a first clinical therapeutic exploration. Acta Psychiat Belg 88: 233–241.

    CAS  Google Scholar 

  • Seeman P (1980) Brain dopamine receptors. Pharmacol Rev 32: 229–313.

    PubMed  CAS  Google Scholar 

  • Squelart P, Saravia J (1977) Pipamperone (Dipiperon), a useful sedative neuroleptic drug in troublesome and chronic psychotic patients. Acta Psychiat Belg 77: 284–293.

    CAS  Google Scholar 

  • Tedeschi DH, Tedeschi RE, Fellows EJ (1961) Central serotonin antagonist activity of a number of phenothiazines. Arch Int Pharmacodyn 132: 172–179.

    PubMed  CAS  Google Scholar 

  • Waddington JL (1988) Therapeutic potential of selective D1 dopamine receptor agonists and antagonists in psychiatry and neurology. Gen Pharmacol 19: 55–60.

    Article  PubMed  CAS  Google Scholar 

  • Waldmeier PC, Delini-Stula AA (1979) Serotonin-dopamine interactions in the nigrostriatal system. Eur J Pharmacol 55: 363–373.

    Article  PubMed  CAS  Google Scholar 

  • Woolley DW (1962) The biochemical bases of psychoses. On the serotonin hypothesis about mental diseases. Wiley, New York, pp 131–192.

    Google Scholar 

  • Woolley DW, Shaw E (1954) A biochemical and pharmacological suggestion about certain mental disorders. Proc Nat Acad Sci 40: 228–231.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. C. J. E. Niemegeers
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Awouters
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. A. J. Janssen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitäts-Nervenklinik und Poliklinik Psychiatrie, Sigmund-Freud-Str. 25, 5300, Bonn 1, Deutschland

    Hans-Jürgen Möller (Direktor) & Eva Pelzer (Direktor) & 

Rights and permissions

Reprints and permissions

Copyright information

© 1990 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Niemegeers, C.J.E., Awouters, F., Janssen, P.A.J. (1990). Pharmakologie der Neuroleptika und relevante Mechanismen zur Behandlung von Minussymptomatik. In: Möller, HJ., Pelzer, E. (eds) Neuere Ansätze zur Diagnostik und Therapie schizophrener Minussymptomatik. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-76263-5_18

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-76263-5_18

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-76264-2

  • Online ISBN: 978-3-642-76263-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation